Veloxity Labs will be attending the upcoming PBSS event focused on small molecule preclinical development and IND-enabling strategies.

This session will explore the practical components required to move programs from preclinical studies into IND submission, including DMPK considerations, regulatory strategy, study design and interactions with regulatory agencies.

These topics are critical for sponsors working to align preclinical data generation with downstream regulatory expectations and clinical development timelines.

Callie looks forward to connecting with colleagues across the PBSS community and discussing how high-quality LC-MS bioanalysis and rapid turnaround times support efficient preclinical development and IND readiness. Hope to see you there!